Darnell Cindy Maria, Thompson Jennifer, Stromberg Daniel, Roy Lonnie, Sheeran Paul
Department of Pediatrics, University of Texas Southwestern, Dallas, Texas, USA.
Pediatrics. 2008 May;121(5):e1363-71. doi: 10.1542/peds.2007-1468. Epub 2008 Apr 14.
Sedating critically ill patients often involves prolonged opioid infusions causing opioid tolerance. Naloxone has been hypothesized to limit opioid tolerance by decreasing adenylate cyclase/cyclic adenosine monophosphate activation. The study purpose was to investigate the effect of low-dose naloxone on the maximum cumulative daily fentanyl dose in critically ill children.
We conducted a double-blinded, randomized, placebo-control trial from December 2002 through July 2004 in a university PICU. We enrolled 82 children age 1 day to 18 years requiring mechanical ventilation and fentanyl infusions anticipated to last for >4 days were eligible for enrollment. Those receiving additional oral analgesia or sedation, having a history of drug dependence or withdrawal, or having significant neurologic, renal, or hepatic disease were excluded. In addition to fentanyl infusions, patients received low-dose naloxone or placebo infusions. Medications were adjusted using the Modified Motor Activity Assessment Scale. Withdrawal was monitored using the Modified Narcotic Withdrawal Scale. Intervention was a low-dose naloxone infusion (0.25 microg/kg per hour) and the main outcome variable was the maximum cumulative daily fentanyl dose (micrograms per kilogram per day).
There was no difference in the maximum cumulative daily fentanyl dose between patients treated with naloxone (N = 37) or those receiving placebo (N = 35). Adjustment for the starting fentanyl dose also failed to reveal group differences. Total fentanyl dose received throughout the study in the naloxone group (360 microg/kg) versus placebo (223 microg/kg) was not statistically different. Placebo patients trended toward fewer rescue midazolam boluses (10.7 vs 17.8), lower total midazolam dose (11.6 mg/kg vs 23.9 mg/kg), and fewer rescue fentanyl boluses (18.5 vs 23.9).
We conclude that administration of low-dose naloxone (0.25 microg/kg per hour) does not decrease fentanyl requirements in critically ill, mechanically ventilated children.
对危重症患者进行镇静时,常需长时间输注阿片类药物,这会导致阿片类药物耐受性。有假说认为,纳洛酮可通过降低腺苷酸环化酶/环磷酸腺苷的激活来限制阿片类药物耐受性。本研究旨在探讨低剂量纳洛酮对危重症儿童每日最大累积芬太尼剂量的影响。
2002年12月至2004年7月,我们在一所大学的儿科重症监护病房(PICU)进行了一项双盲、随机、安慰剂对照试验。纳入82例年龄在1天至18岁之间、需要机械通气且预计芬太尼输注持续时间超过4天的儿童。排除那些接受额外口服镇痛或镇静治疗、有药物依赖或戒断史、或有严重神经、肾脏或肝脏疾病的患者。除芬太尼输注外,患者还接受低剂量纳洛酮或安慰剂输注。使用改良运动活动评估量表调整药物剂量。使用改良的阿片类药物戒断量表监测戒断情况。干预措施为低剂量纳洛酮输注(每小时0.25微克/千克),主要结局变量为每日最大累积芬太尼剂量(微克/千克/天)。
接受纳洛酮治疗的患者(N = 37)与接受安慰剂治疗的患者(N = 35)在每日最大累积芬太尼剂量上无差异。对起始芬太尼剂量进行调整后,也未发现组间差异。纳洛酮组在整个研究期间接受的芬太尼总剂量(360微克/千克)与安慰剂组(223微克/千克)相比,差异无统计学意义。安慰剂组患者使用抢救用咪达唑仑推注的次数有减少趋势(10.7次对17.8次),咪达唑仑总剂量较低(11.6毫克/千克对23.9毫克/千克),抢救用芬太尼推注次数也较少(18.5次对23.9次)。
我们得出结论,对于危重症、机械通气的儿童,给予低剂量纳洛酮(每小时0.25微克/千克)并不会降低芬太尼的需求量。